Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
29 July 2019 | Story Leonie Bolleurs
Dr Martin Clark
Dr Martin Clark, the founder of the MAGIC (Multi-purpose Aerial Geological Image Classification) initiative. MAGIC can obtain geological and structural information that is critical for making informed decisions in exploration and mineral extraction processes.

Mining has historically been described as a boom-and-bust industry, where fluctuations in mineral prices could result in extreme success or bankruptcy. Successful mining companies closely monitor assets/expenditures, risks, and other parameters associated with their business to best ensure their longevity. In most mineral industries, there are a few competitors that dominate the delivery of a mineral resource. As a result, technological development, along with other factors, are critical to ensure that these companies’ business remains viable and protected.

This is according to post-doctoral fellow in the Department of Geology, Dr Martin Clark.

Drone technology: better, faster, safer

He says technological development in mining generally translates to how a company can extract a resource from the ground better, faster, and safer. 

Dr Clark believes the rapid development of drone technology represents a shift in the toolbox that mining companies can employ.

“Drones can collect a great deal of data randomly over vast or small areas within hours, historically accomplished by mapping campaigns which can last months to years. Drones can also collect data in areas which are difficult and dangerous for humans to get to. These include cliff faces or rock walls that are difficult and dangerous to get close to, as well as stretches of land where dense vegetation, inaccessible terrain, and even atmospheric dangers become factors which reduce or modify the scope of exploration work,” he said. 

Expanding application of drones

Dr Clark’s work specifically focuses on expanding the applications for which drones are used. “I assess what and how good the imaging capabilities of drones are, use the imagery to generate 3-D models to drive scientific observation, and yield results which can help companies to extract resources. This initiative is called MAGIC (Multi-purpose Aerial Geological Image Classification),” he said. 



“MAGIC aims to collect geological and structural information that is critical for making informed decisions in exploration and mineral extraction processes,” he added.

Dr Clark is not only the founder of MAGIC; he also drives multiple aspects of the initiative including education, research, and business development. 

In 2013, when he was busy with his doctorate, there was already a spark of interest in using drones to address geological questions. At that time, Dr Clark was working with remotely sensed high-resolution LiDAR imagery to better understand geological structures at the Sudbury Mining Camp in Canada. The interest became a reality in 2018, when he applied this initiative during his post-doctoral fellowship at the UFS.

Now and the future

“At present, there are no direct mining projects underway, but projects are expected to begin in 2020. Drone operation and image-analysis techniques are currently being refined for industry,” he said. 

Besides his work with drones, Dr Clark also work in the fields of structural geology, remote sensing, and geospatial data analysis.  

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept